Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Alkem"

36 News Found

Alkem Labs to launch treatment for Diabetic Foot Ulcer
News | January 12, 2022

Alkem Labs to launch treatment for Diabetic Foot Ulcer

This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates


Alkem Laboratories PAT at Rs 468.12 crore for Q1FY22
News | August 08, 2021

Alkem Laboratories PAT at Rs 468.12 crore for Q1FY22

EPS stood at Rs 39.15


Alkem launches Ibuprofen and Famotidine tablets in US
News | August 07, 2021

Alkem launches Ibuprofen and Famotidine tablets in US

Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg


Alkem launch two drugs in US
News | August 04, 2021

Alkem launch two drugs in US

Ibuprofen and Famotidine tablets approved by FDA


Alkem launches Perampil tablets at affordable prices
News | June 11, 2021

Alkem launches Perampil tablets at affordable prices

The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access


Alkem Q4FY21 consolidated PAT drops QoQ to Rs. 239.99 Cr
News | May 25, 2021

Alkem Q4FY21 consolidated PAT drops QoQ to Rs. 239.99 Cr

It posted net profit of Rs.188.77 crores for the period ended March 31, 2020.


Steady performance; for Alkem Laboratories: ICICI Securities
News | February 13, 2021

Steady performance; for Alkem Laboratories: ICICI Securities

The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21


Aurobindo Pharma appoints N. Ravikiran as Chief Business Officer
People | March 07, 2024

Aurobindo Pharma appoints N. Ravikiran as Chief Business Officer

Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis


75% of asthma patients have worse symptoms during cold or flu
Healthcare | January 25, 2023

75% of asthma patients have worse symptoms during cold or flu

Asthma patients are more likely to have an asthma attack during winter


JBCPL emerges as the fastest growing pharma company: Report
News | May 05, 2022

JBCPL emerges as the fastest growing pharma company: Report

Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22